313 related articles for article (PubMed ID: 10912578)
1. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
2. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
3. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
4. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil.
Yamashita T; Ueda Y; Fuji N; Itoh T; Kurioka H; Shirasaka T; Yamagishi H
Cancer Chemother Pharmacol; 2006 Aug; 58(2):183-8. PubMed ID: 16317557
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
8. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
11. [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi T; Tanaka G; Irimura K; Hirota T; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():495-504. PubMed ID: 9021658
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
16. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.
Shirasaka T; Shimamoto Y; Fukushima M
Cancer Res; 1993 Sep; 53(17):4004-9. PubMed ID: 7689420
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
18. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Moriyama K; Kouchi Y; Morinaga H; Irimura K; Hayashi T; Ohuchida A; Goto T; Yoshizawa Y
Toxicology; 2006 Jan; 217(2-3):233-9. PubMed ID: 16278042
[TBL] [Abstract][Full Text] [Related]
19. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
Yoshisue K; Nagayama S; Shindo T; Kawaguchi Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):1166-75. PubMed ID: 11356943
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]